Abstract
Two studies recently reported around 10% of EGFR activating mutations in triple negative breast cancers from Asian patients. However, we did not find any EGFR activating mutation in a series of 229 breast tumor samples from European patients. Like in lung cancer, the EGFR mutation profiles seem to be related to the ethnical origin of patients. This is an important point that should be considered when developing anti-EGFR therapies.
Highlights
Two studies recently reported around 10% of Epidermal Growth Factor Receptor (EGFR) activating mutations in triple negative breast cancers from Asian patients
Commentary We have read with great interest the study on Epidermal Growth Factor Receptor (EGFR) mutations in breast carcinoma by Ning Lv et al published in Diagnostic Pathology [1]
Since in lung cancer the choice of anti-EGFR therapy is based on the presence of EGFR activating mutations, and due to the importance to the EGFR pathway in breast cancer, it is crucial to evaluate the presence of these mutations in the different subtypes of breast cancer
Summary
Two studies recently reported around 10% of EGFR activating mutations in triple negative breast cancers from Asian patients. Commentary We have read with great interest the study on Epidermal Growth Factor Receptor (EGFR) mutations in breast carcinoma by Ning Lv et al published in Diagnostic Pathology [1]. Since in lung cancer the choice of anti-EGFR therapy is based on the presence of EGFR activating mutations, and due to the importance to the EGFR pathway in breast cancer, it is crucial to evaluate the presence of these mutations in the different subtypes of breast cancer. The authors reported that, in their series of 139 breast cancers, two (1.4%) tumors harbored activating EGFR mutations in exon 19 and 21 of this gene.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.